Commentary · 21 Feb 2026
Conference abstractPublished 10 Sep 2012
From in silico discovery to anti-cancer activity: Targeting the non-ATP binding site of C-Jun N-terminal Kinase
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Due to their role in cellular signaling, mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. Most MAP kinase inhibitors target the highly conserved ATP binding site. This conservation promotes cross-reactivity and toxicities that may limit their potential as drugs. These drawbacks motivate the search for non-ATP competitive inhibitors with acceptable specificity and potency. We applied a virtual screening (VS) workflow to discover novel scaffolds for non ATP-competitive JNK (C-Jun N-terminal Kinase) inhibitors targeting the JNK-JIP (JNK Interacting Protein) interaction. (-)-Zuonin A was identified as an inhibitor of JNK, exhibiting 100-fold selectivity for the JNKs over other MAP kinases. (-)-Zuonin A was characterized extensively both in vitro and in cellular breast cancer models. The JNK2 isoform has been reported to regulate breast cancer cell migration. Accordingly, we engineered a JNK2-selective peptide inhibitor. Peptides derived from the JIP scaffolds linked to the cell-penetrating peptide TAT are used widely to investigate JNK-mediated signaling events without exhibiting isoform selectivity. Herein, Several JIP-based peptide sequences were designed and tested. A JIP sequence connected through a flexible linker to either the N-terminus of an inverted TAT sequence (JIP 10 -∆- TAT i ), or to a poly-arginine sequence (JIP 10 -∆-R 9 ) enabled the potent inhibition of JNK2 (IC 50 ~90 nM) with 10-fold selectivity over JNK1 and JNK3. Both peptides revealed an ability to inhibit the induction of JNK activation and c-Jun phosphorylation in HEK293T cells treated with anisomycin, and inhibited the migration of Polyoma Middle-T Antigen Mammary Tumor (PyVMT) cells through the selective inhibition of JNK2.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Tamer S. Kaoud”
- BylineArticles whose byline prints “Kevin N. Dalby”
